Spontaneous Rejection of Poorly Immunogenic P1.HTR Tumors by Stat6-Deficient Mice
- 1 December 2000
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 165 (11) , 6024-6028
Abstract
Experimental evidence suggests that a type 1 T cell response may result in optimal tumor rejection in vivo. This phenotype is determined in part by cytokines that influence T cell differentiation. In transplantable tumor models such as P1.HTR, tumors grow progressively despite expression of defined tumor Ags. We hypothesized that this failure to reject may be due to poor generation of a type 1 phenotype, through a dominant influence of the type 2-promoting cytokines IL-4 and/or IL-13. This hypothesis was tested by implanting P1.HTR tumors into mice deficient in Stat6. In contrast to progressive growth of P1.HTR tumors in wild-type mice, and aggressive growth even of IL-12-transfected P1.HTR in Stat1−/− mice, P1.HTR was spontaneously rejected by Stat6−/− mice. Rejection was accompanied by augmented tumor-specific IFN-γ production and CTL activity. These results suggest that pharmacologic inhibition of Stat6 signaling could potentiate anti-tumor immunity in vivo.Keywords
This publication has 29 references indexed in Scilit:
- IL-13, IL-4Rα, and Stat6 Are Required for the Expulsion of the Gastrointestinal Nematode Parasite Nippostrongylus brasiliensisImmunity, 1998
- Interleukin-4 and lnterleukin-13: Their Similarities and DiscrepanciesInternational Reviews of Immunology, 1998
- Stat6 Is Required for Mediating Responses to IL-4 and for the Development of Th2 CellsImmunity, 1996
- Targeted Disruption of the Mouse Stat1 Gene Results in Compromised Innate Immunity to Viral DiseaseCell, 1996
- Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunityNature Medicine, 1995
- Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma.Proceedings of the National Academy of Sciences, 1995
- Inhibition of tumor growth by elimination of granulocytes.Journal of Experimental Medicine, 1995
- The presence of interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4+ T cells from T cell receptor transgenic mice.Journal of Experimental Medicine, 1992
- Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells.Journal of Experimental Medicine, 1992
- Selection of highly transfectable variant from mouse mastocytoma P815Somatic Cell and Molecular Genetics, 1985